Clinical Trial Update: ASCERV Study: MRG003 Combined With QL1706 in Recurrent or Metastatic Cervical Cancer [Phase 1, Phase 2]

View source ↗

Summary

The ASCERV study is evaluating the combination of MRG003 and QL1706 in recurrent or metastatic cervical cancer, with Phase 1 and Phase 2 arms. The trial is curr…

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Cervical Cancer

Drugs mentioned

• MRG003
• QL1706

Snippet

Sponsor: Second Affiliated Hospital, School of Medicine, Zhejiang University | Conditions: Recurrent or Metastatic Cervical Cancer | Phase 1, Phase 2 | Status: NOT_YET_RECRUITING